Core Viewpoint - Kaineng Health plans to acquire 100% equity of four target companies for approximately 204 million yuan, aiming to deepen its presence in the health industry and establish a second growth curve in the cell industry [1][2]. Group 1: Acquisition Details - The acquisition involves Kaineng Health's wholly-owned subsidiary, Kaineng Health Cell Industry (Hainan) Co., Ltd., purchasing equity from Yuaneng Cell Technology Group Co., Ltd. and Yuaneng Cell (Lishui) Industrial Development Co., Ltd. [1] - The target companies include Shanghai Yuan Tian Biotechnology Co., Ltd., Lishui Dongxin Pharmaceutical Co., Ltd., Shanghai Kelemao Biotechnology Co., Ltd., and Jiyuan Meiyu Biotechnology (Shanghai) Co., Ltd. [1][2]. Group 2: Business Focus of Target Companies - The target companies cover various sectors such as cell preparation, laboratory animal services, and cell technology cosmetics [2]. - Shanghai Yuan Tian focuses on stem cell and immune cell preparation technologies, holding 44 authorized patents [2]. - Lishui Dongxin serves as an investment holding platform without substantial operations, while its subsidiary provides laboratory animal breeding and experimental support [2]. - Jiyuan Meiyu specializes in skin cell repair and regeneration technology, and Kelemao has not yet commenced operations [2]. Group 3: Strategic Implications - The acquisition is intended to enhance Kaineng Health's strategic layout in the health industry and improve its overall competitiveness and sustainable development capabilities [2]. - Entering the stem cell industry aligns with the company's long-term strategic development plan [2].